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Skin lesions are associated with Crohns disease (CD) in 22–
44% of patients. Metastatic Crohn's disease (MCD) is defined as
granulomatous skin lesions occurring at sites separate from
the gastrointestinal tract, mainly in the lower extremities
and intertriginous areas.1 Genital MCD has been frequently
described as refractory and usually begins as a non-healing
ulcer, but can be shown as a papule, plaque or swelling.2
We describe the case of a 24-year-old male who presented
with ulcers in the penile foreskin area two weeks before
admission in the Urology department. He was diagnosed with
colonic and perianal CD at 9 years old (A1L3B2p). He has had
multiple exacerbations since then, which only responded
partially to azathioprine, infliximab and adalimumab. He has
had a right colostomy and left mucous fistula since 2008,
treated with azathioprine. Two months before, the patient
had clinical worsening due to tenesmus, mucus discharge from
the rectal stump, abdominal pain, and weight loss, with aFigure 1 Evolution of penile metastatic Crohn's disease. (A) Ulcera
(B) Recurrence of ulcerative lesion after surgery and final of inductio
after tacrolimus ointment topical treatment.
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last week (Fig. 1A).
Metronidazole and intravenous corticosteroids previous
treatment were not effective, so we decided to perform
circumcision and surgical removal of the lesion. Histology
showed non-caseating granulomas, palisading histiocytes
and giant cells compatible with MCD. We started treatment
with adalimumab at an induction dose of 160 mg followed by
80 mg for 2 weeks, continuing with a maintenance dose of
40 mg eow with good initial progress.
At the end of the induction period, recurrence was
observed with deep ulceration on the dotted line with a
progressive increase in size and purulent exudate (Fig. 1B),
so we initiated twice-daily therapy with tacrolimus 0.1%
ointment for 4 weeks and subcutaneous adalimumab was
continued. The response to topical application was fast, with
improvement of the lesions after the first 24 h, progressive
scarring and complete resolution in 18 days (Fig. 1C); no
recurrences were observed during follow-up (18 months).ted penile in foreskin area before surgical removal of the lesion.
n period with adalimumab. (C) Complete healing of penile lesion
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1146 EDITORIALSkin involvement in CD has been classified as specific
lesions (both contiguous perianal CD and distant cutaneous
MCD), reactive skin findings (erythema nodosum and
pyoderma gangrenosum) and nutritional changes secondary
to malabsorption.3
Different therapeutic strategies have been reported
(steroids, ciclosporin, thyopurines, antibiotics, and hyperbaric
oxygen) being in most patients, treatment with biological
agents (infliximab or adalimumab) is highly effective.4,5
Surgical debridement also seems to be adequate, especially
in refractory cases.
Altogether, we showed a complicated case of postoper-
ative recurrent MCD of the penis that occurred at the end of
induction treatment with adalimumab where topical tacro-
limus treatment helped to heal the lesion. Because of the
improvement of the lesions, we continued with the sched-
uled maintenance dosage (40 mg eow) without needing to
increase treatment, an option that must be considered in
MCD undergone biological treatment.Conflict of interest
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